This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mattsson J, Ringdén O, Storb R . Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14 (Supplement 1): 165–170.
Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K et al. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant 2014; 49: 110–115.
Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant 2011; 17: 841–851.
Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori S et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2012; 18: 1407–1414.
Yamamoto H, Kato D, Uchida N, Ishiwata K, Araoka H, Takagi S et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood 2011; 117: 3240–3242.
Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586–3592.
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000; 111: 292–302.
McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233–237.
Shimizu I, Kobayashi H, Nasu K, Otsuki F, Ueki T, Sumi M et al. Successful engraftment of cord blood following a one-day reduced-intensity conditioning regimen in two patients suffering primary graft failure and sepsis. Bone Marrow Transplant 2009; 44: 617–618.
Yamashita T, Sugimori C, Ishiyama K, Yamazaki H, Okumura H, Kondo Y et al. Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections. Int J Hematol 2009; 89: 238–242.
Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, Ueno M et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol 2010; 92: 744–750.
Kristt D, Stein J, Yaniv I, Klein T . Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant 2007; 39: 255–268.
Bishton M, Chopra R . The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004; 127: 501–508.
Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG et al. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant 2013; 19: 1480–1492.
Gallot G, Vollant S, Saiagh S, Clemenceau B, Vivien R, Cerato E et al. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother 2014; 37: 170–179.
Acknowledgements
We are grateful to the medical, nursing and laboratory staff of the participating departments for their contributions to this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ishiyama, K., Takeda, J., Kondo, T. et al. Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation. Bone Marrow Transplant 51, 985–987 (2016). https://doi.org/10.1038/bmt.2016.16
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.16
This article is cited by
-
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen
International Journal of Hematology (2019)
-
Melphalan
Reactions Weekly (2016)